Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients
Authors' conclusion
Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.
Study context
- Population
- Patients with refractory inflammatory myositis treated with tofacitinib, single urban centre, Vancouver, Canada, June 2016–December 2022
- Participants
- 41 patients
- Exposure
- Classic DM vs amyopathic DM (ADM) vs PM
- Classic DMn = 23
- ADMn = 12
- PMn = 6
- Outcome
- Efficacy of tofacitinib
Methodological detailssingle-centre, real-world, Patients failed an average of four to five non-steroidal immunosuppressants before tofacitinib
- Single-centre
- Real-world
- Patients failed an average of four to five non-steroidal immunosuppressants before tofacitinib
Main finding
As reported in the abstract
- Classic DM and ADM: clinically and statistically significant cutaneous improvement
- All myositis patients incl. PM phenotype: no meaningful muscle strength response
Observational data: associations, not effects.
Further findings
Discontinuation of tofacitinib due to lack of benefit or death
- Patients discontinuing tofacitinib
- 53.7%
Cutaneous disease activity in patients remaining on tofacitinib at study conclusion (n=19)
- Clinically and statistically significant improvement in cutaneous disease activity
Original publication
Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). Published 16 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →